Nls pharmaceutics announces the launch of a preclinical program for mazindol er in the treatment of fentanyl dependence

Centers for disease control and prevention (the "cdc") reported 105,007 drug overdose deaths - with 90% involving synthetic opioids like fentanyl mazindol er potentially offers a non-opioid alternative, addressing the underlying neurochemical imbalances associated with fentanyl addiction. mazindol er is patent protected beyond september 2038 zurich , jan. 28, 2025 /prnewswire/ --  nls pharmaceutics ltd.
NLSP Ratings Summary
NLSP Quant Ranking